• PHP95 THE DOS AND DONTS IN PAYER COMMUNICATION. A QUALITATIVE RESEARCH ACROSS FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • CE1 COST-EFFECTIVENESS ANALYSIS OF GLUCOSAMINE SULPHATE FOR THE TREATMENT OF OSTEOARTHRITIS IN THAILAND

    Nov 1, 2010, 00:00

  • PHP134 IMPACT OF BLEEDING-RELATED CONSEQUENCES ON LENGTH OF STAY (LOS) AND HOSPITAL COSTS IN PATIENTS UNDERGOING SURGERY IN FRANCE

    Nov 1, 2010, 00:00

  • PDB28 HEALTH INSURANCE COST OF DIABETES MELLITUS IN HUNGARY- A COST OF ILLNESS STUDY

    Nov 1, 2010, 00:00

  • PHP20 QUALITY ASSURANCE OF FOURTH HURDLE CONCERNING TO MEDICAL DEVICES

    Nov 1, 2010, 00:00

  • CN2 A SYSTEMATIC REVIEW AND META-ANALYSIS OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER

    Nov 1, 2010, 00:00

  • PHP10 DOES THE MARKET SHARE OF GENERIC MEDICINES INFLUENCE THE PRICE LEVEL? A EUROPEAN ANALYSIS

    Nov 1, 2010, 00:00

  • PCV22 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA

    Nov 1, 2010, 00:00

  • PSS22 INDIRECT COSTS OF INFORMAL CARE FOR ONE EPISODE OF ACUTE OTITIS MEDIA IN GERMANY

    Nov 1, 2010, 00:00

  • PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

    Nov 1, 2010, 00:00

  • PDB43 LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VS. SULPHONYLUREA IN POLAND

    Nov 1, 2010, 00:00

  • PMH39 THE COST-UTILITY OF AGOMELATINE IN MAJOR DEPRESSIVE DISORDER IN POLAND

    Nov 1, 2010, 00:00

  • PHP31 WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR- IS ONE THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?

    Nov 1, 2010, 00:00

  • PMH34 COST-EFFECTIVENESS ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA- 24-MONTH DATA FROM CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PDB71 QUALITY-ADJUSTED LIFE-YEAR (QALY) WEIGHTS ASSOCIATED WITH DIFFERENT SEVERITY LEVELS OF DIABETIC RETINOPATHY

    Nov 1, 2010, 00:00

  • PIN19 HEPATITIS C BURDEN IN RUSSIA

    Nov 1, 2010, 00:00

  • PMS62 CERTOLIZUMAB PEGOL MONOTHERAPY PROVIDES SUSTAINED IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY AND DAILY ACTIVITIES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS OVER 2 YEARS

    Nov 1, 2010, 00:00

  • PCN110 RESOURCE UTILIZATION AND DIAGNOSTIC APPROACHES IN NON-SMALL-CELL LUNG CANCER (NSCLC) ACROSS EUROPE- EPICLIN-LUNG STUDY

    Nov 1, 2010, 00:00

  • PDB78 WILLINGNESS-TO-PAY FOR DIABETES DRUG THERAPY BASED ON META-ANALYSIS RESULTS

    Nov 1, 2010, 00:00

  • PSS8 PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COST IN GERMANY

    Nov 1, 2010, 00:00

  • PRS6 DEVELOPING AND APPLYING A STOCHASTIC DYNAMIC POPULATION MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2010, 00:00

  • PIH14 VALIDITY OF EQ-5D AND SF-12 AMONG MALAYSIAN

    Nov 1, 2010, 00:00

  • PND3 EFFICACY AND TOLERABILITY OF INTERFERON-BETA IN ALL TYPE OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PCN90 COMPARATIVE RETROSPECTIVE NON-RANDOMIZED PHARMACOECONOMIC TRIAL OF EFFICIENCY AND SAFETY OF USE OF PACLITAXELS (PACLITAXEL-LENS OR TAXOL) IN A MONOMODE FOR 2ND LINE OF TREATMENT OF METASTATIC BREAST CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PRS16 PITFALLS IN THERAPEUTIC REFERENCE PRICING PRACTICE OF THE MEDICATION OF ASTHMA

    Nov 1, 2010, 00:00

  • PCN66 ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED COLON-RECTUM CANCER IN CHINA

    Nov 1, 2010, 00:00

  • PUK21 LONG-TERM COST-EFFECTIVENESS OF SIROLIMUS BASED REGIMEN COMPARED WITH CALCINEURIN INHIBITOR BASED REGIMENS IN LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS IN KOREA

    Nov 1, 2010, 00:00

  • CV1 USING REAL WORLD DATA TO CALCULATE THE COST-EFFECTIVENESS OF STATIN AMONG PARTICIPNATS WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIAN GENERAL PRACTICE

    Nov 1, 2010, 00:00

  • PND28 COST-UTILITY ANALYSIS OF ROTIGOTINE TRANSDERMAL PATCH IN EARLY-STAGE PARKINSONS DISEASE IN SCOTLAND

    Nov 1, 2010, 00:00

  • PRS20 OUTCOMES ASSOCIATED WITH IATROGENIC PNEUMOTHORAX

    Nov 1, 2010, 00:00

  • PDB45 COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN

    Nov 1, 2010, 00:00

  • PHP37 PRIORITIZATION OF HEALTH POLICY AND SYSTEM RESEARCH TOPICS IN THAILAND- MAKING IT SYSTEMATIC, TRANSPARENT AND PARTICIPATORY

    Nov 1, 2010, 00:00

  • PHP81 EFFECTS OF THE POTENCIAL GENERIC SUBSTITUTION IN PORTUGAL. DOES REGULATION MATTERS?

    Nov 1, 2010, 00:00

  • PMS9 HEALTH-RELATED QUALITY OF LIFE IN INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PHP25 DOES HUMAN MEDICINES DEVELOPMENT IN THE EUROPEAN UNION ADDRESS GLOBAL AND REGIONAL HEALTH CONCERNS?

    Nov 1, 2010, 00:00

  • PCV127 INCREASING NURSE STAFFING LEVELS IN BELGIAN CARDIAC SURGERY CENTERS- A COST-EFFECTIVE PATIENT SAFETY INTERVENTION?

    Nov 1, 2010, 00:00

  • PCN24 A POPULATION-BASED DECISION ANALYTIC MODEL FOR ASSESSING THE HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM

    Nov 1, 2010, 00:00

  • PCV14 ASPIRIN USE IS NOT ASSOCIATED WITH REDUCED MYOCARDIAL INFARCTION IN ELDERLY WITH TYPE 2 DIABETES WITH OR WITHOUT PRIOR HISTORY OF CARDIOVASCULAR DISEASE

    Nov 1, 2010, 00:00

  • PSS1 EPIDEMIOLOGY AND COMORBIDITIES OF PATIENTS WITH PSORIASIS N TAIWAN

    Nov 1, 2010, 00:00

  • PCN51 HOSPITALIZATION COSTS FOR HPV-RELATED CANCERS IN MALES AND FEMALES IN FRANCE

    Nov 1, 2010, 00:00

  • PMC36 SYSTEMATIC REVIEW OF THE RESPONSIVNESS OF SF-36 HEALTH SURVEY MEASURES TO EFFICACIOUS PHARMACEUTICAL THERAPIES IN WELL-CONTROLLED CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PND19 A LONG-TERM COST-EFFECTIVENESS MARKOV MODEL COMPARING DISEASE MODIFYING TREATMENTS IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

    Nov 1, 2010, 00:00

  • PIN25 SEASONAL INFLUENZA VACCINATION OF HEALTHY, WORKING-AGE ADULTS- A SYSTEMATIC REVIEW OF ECONOMIC INVESTIGATIONS

    Nov 1, 2010, 00:00

  • PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D)- ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GL ...

    Nov 1, 2010, 00:00

  • PCV133 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009- BASELINE RESULTS FOR GERMANY FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Nov 1, 2010, 00:00

  • PHP18 SCIENTIFIC EVIDENCE FOR THE RELATIONSHIP BETWEEN PHARMACEUTICAL BUDGET OF HEALTH INSURANCE FUND AND THE POLITICAL ELECTION CIRCLES IN HUNGARY

    Nov 1, 2010, 00:00

  • PIH37 RELATIONSHIP BETWEEN HEALTH-CARE PROFESSIONALS ND POPULATION HEALTH STATUS- DO NUMBERS COUNT?

    Nov 1, 2010, 00:00

  • PUK11 A COST EVALUATION OF PERITONEAL DIALYSIS AND HEMODIALYSIS IN THE TREATMENT OF ESRD IN SO PAULO, BRAZIL

    Nov 1, 2010, 00:00

  • PSY13 COST IMPACT FROM INITIATING PREGABALIN TREATMENT IN PATIENTS WITH REFRACTORY NEUROPATHIC PAIN

    Nov 1, 2010, 00:00

  • PCV35 POTENTIAL DRUG-DRUG INTERACTIONS RELATED TO ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV134 THERAPEUTIC VERSUS ACTUAL MARKET SHARES FOR STATINS

    Nov 1, 2010, 00:00

  • PCN111 HEALTH-CARE RESOURCE UTILIZATION IN ADVANCED MELANOMA- AN ANALYSIS FROM THE MELODY OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PIH15 SENSITIVITY OF GENERIC PATIENT-REPORTED OUTCOMES MEASURES AMONG CAREGIVERS OF CHILDREN WITH CRANIOFACIAL MALFORMATION

    Nov 1, 2010, 00:00

  • PDB91 TREATMENT PATTERNS AND ACHIEVEMENT OF THERAPEUTIC GOALS IN A COHORT OF TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM (PHCS)- INITIAL REPORTS OF DIAPS 79 STUDY

    Nov 1, 2010, 00:00

  • PRS46 ADJUSTING FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SEVERITY IN DATABASE RESEARCH- FEASIBILITY OF DEVELOPING AND VALIDATING AN ALGORITHM

    Nov 1, 2010, 00:00

  • PSS8 COST-EFFECTIVENESS OF BRINZOLAMIDE/TIMOLOL FIXED COMBINATION (BTFC) VERSUS DORZOLAMIDE/TIMOLOL FIXED COMBINATION (DTFC) FOR PATIENTS WITH OPEN ANGLE GLAUCOMA IN KOREA AND TAIWAN

    Nov 1, 2010, 00:00

  • PDB25 DIABETES-RELATED COMPLICATIONS AND GLYCEMIC CONTROL IN TYPE 2 DIABETIC MELLITUS PATIENTS AT SPECIALIST OUTPATIENT CLINICS IN SINGAPORE

    Nov 1, 2010, 00:00

  • PIH11 SOCIETAL IMPACT OF DIARRHEA IN YOUNG CHILDREN IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

    Nov 1, 2010, 00:00

  • PIN4 SURGICAL SITE INFECTION IN JAPAN-A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PCN166 DEVELOPMENT OF A FLAG SYSTEM FOR THE COMPUTERIZED DETECTION OF CANCER PATIENTS WITH ADDITIONAL TREATMENT NEEDS BY MEANS OF THE 'COMPUTER BASED HEALTH EVALUATION SYSTEM' (CHES)

    Nov 1, 2010, 00:00

  • PRS34 IMPROVED PREDICTION OF FINDING COPD PATIENTS BY LUNG FUNCTION PRE-SCREENING IN PRIMARY CARE

    Nov 1, 2010, 00:00

  • PRS40 EVALUATION OF SMOKING CESSATION DRUG USE AND OUTCOMES IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PGI20 MEDICATION ADHERENCE AND PERSISTENCE IN THE TREATMENT OF ULCERATIVE COLITIS- ANALYSES WITH THE RAMQ DATABASE

    Nov 1, 2010, 00:00

  • PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE-A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA

    Nov 1, 2010, 00:00

  • PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCV21 MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH DIAGNOSTIC AND PROGNOSTIC INFORMATION

    Nov 1, 2010, 00:00

  • PHP39 THE EFFECTS OF DIRECT BILLING SYSTEM IN PATIENTS WITH CIVIL-SERVANT MEDICAL BENEFIT SCHEMES ON PRESCRIBING PATTERNS

    Nov 1, 2010, 00:00

  • PHP30 VANCOMYCIN UTILIZATION EVALUATION IN A TEACHING HOSPITAL BETWEEN FEBRUARY 2007 AND MAY 2008 IN IRAN

    Nov 1, 2010, 00:00

  • PND1 OUTCOME OF PHARMACIST INTERVENTION IN EDUCATION OF PATIENTS ON DUPLICATE PRESCRIPING HYPNOTIC-SEDATIVES

    Nov 1, 2010, 00:00

  • PMH47 MEDICATION COMPLIANCE AND HEALTH CARE COSTS OF TYPE II DIABETICS WITH SCHIZOPHRENIA NEWLY STARTING HYPOGLYCEMIC THERAPY

    Nov 1, 2010, 00:00

  • PRS31 SHOULD SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) BE ADDED TO ROUTINE COPD TREATMENT WITH FENOTEROL/ IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC ASSESSMENT OF COPD TREATMENT BASED ON OBSERVATIONAL RESEARCH (PHACTOR)

    Nov 1, 2010, 00:00

  • PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI ...

    Nov 1, 2010, 00:00

  • PIN42 THE COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) COMPARED WITH 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) IN TAIWAN

    Nov 1, 2010, 00:00

  • PMC42 TO WHAT EXTENT CAN TECHNOLOGY IMPROVE THE VALIDITY OF CLINROS?

    Nov 1, 2010, 00:00

  • PCV71 IS COREVALVE A COST-EFFECTIVE TREATMENT FOR PATIENTS WITH SEVERE AORTIC STENOSIS WHO SATISY ALL THE CRITERIA FOR CONVENTIONAL AORTIC VALVE REPLACEMENT?

    Nov 1, 2010, 00:00

  • PRS26 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF MOMETASONE FUROATE AS MAINTENANCE TREATMENT IN PATIENTS WITH MILD TO MODERATE ASTHMA FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PHP38 COMPLEXITY INCREASES UNCERTAINTY-THE IMPACT OF PBAC GUIDELINES (VERSION 4) ON PBAC DECISION-MAKING

    Nov 1, 2010, 00:00

  • PGI12 ECONOMIC CONSEQUENCES OF POORLY CONTROLLED PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE IN GERMANY, ITALY AND SPAIN

    Nov 1, 2010, 00:00

  • PSY59 ACCESSIBILITY AND UTILIZATION OF BORTEZOMIB IN DUTCH DAILY PRACTICE

    Nov 1, 2010, 00:00

  • PUK15 RESOURCE USE AND COSTS OF PATIENTS UNDERGOING DIALYSIS IN BELGIUM

    Nov 1, 2010, 00:00

  • PCN71 A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PMH17 COST OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN GERMANY

    Nov 1, 2010, 00:00

  • PCN91 BEVACIZUMAB S PERSPECTIVE

    Nov 1, 2010, 00:00

  • PND22 COST-EFFECTIVENESS ANALYSIS COMPARING BRIDION (SUGAMMADEX) WITH NEOSTIGMIN AND SPONTANEOUS RECOVERY IN THE REVERSAL OF NEUROMUSCULAR BLOCKADE INDUCED BY ROCURONIUM/VECURONIUM

    Nov 1, 2010, 00:00

  • PCV131 AN INTERNATIONAL COMPARISON OF DUAL ANTIPLATELET USE BY STENT TYPE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE AFTER ACUTE CORONARY SYNDROME- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)

    Nov 1, 2010, 00:00

  • PIN62 AN ECONOMIC EVALUATION OF HIBMENCY VACCINATION FOR THE PREVENTION OF HEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS TYPES C AND Y

    Nov 1, 2010, 00:00

  • PMS28 COST-EFFICACY ANALYSIS OF TNF ALPHA ANTAGONISTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PDB26 ECONOMIC BURDEN OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY IN KOREA

    Nov 1, 2010, 00:00

  • PDB62 COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PCV138 MEASUREMENT PROPERTIES OF PEAK VO2 IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PMH29 COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA IN SPAIN- DIABETES AND CORONARY HEART DISEASE PROJECTIONS (STAR STUDY)

    Nov 1, 2010, 00:00

  • PSS5 HEALTH RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN THAILAND- PRELIMINARY FINDINGS

    Nov 1, 2010, 00:00

  • BI4 ARE SECOND OPINIONS OBJECTIVE? BIASES IN SECOND-OPINION CONSULTATIONS

    Nov 1, 2010, 00:00

  • PMC6 ESTIMATING EQ-5D TARIFFS FOR MALAYSIA USING TIME TRADE OFF AND VISUAL ANALOGUE SCALE

    Nov 1, 2010, 00:00

  • PIH10 TREATMENT AND COST FOR PATIENTS WITH ENDOMETRIOSIS IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PHP84 A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING RESTRICTIONS

    Nov 1, 2010, 00:00

  • PMS16 EARLY MORTALITY RATE OF BILATERAL HIP FRACTURES OVER 60 IN HUNGARY

    Nov 1, 2010, 00:00

  • PDB1 CLINICAL OUTCOMES WITH DPP4 INHIBITORS IN SINGAPORE

    Nov 1, 2010, 00:00

  • PIH17 GENERAL PUBLIC SATISFACTION TOWARD THE PROVISION OF HEALTH-CARE DELIVERY BY GOVERNMENT HOSPITALS AND CLINICS IN THE STATE OF PENANG

    Nov 1, 2010, 00:00

  • PHP21 WHAT ARE THE TOP MOST COSTLY DISEASES FOR USA? THE ALIGNMENT OF BURDEN OF ILLNESS WITH PREVENTION AND SCREENING EXPENDITURES

    Nov 1, 2010, 00:00

  • PRS24 LONG-TERM EFFECTIVENESS AND COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN PATIENTS WITH COPD

    Nov 1, 2010, 00:00

  • PDB11 CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS- A MODELING ANALYSIS IN THE CHINESE SETTING

    Nov 1, 2010, 00:00

  • PHP78 A TALE OF FOUR COUNTRIES- COMPARING REIMBURSEMENT SUBMISSION REQUIREMENTS IN IRELAND, ENGLAND, WALES AND SCOTLAND

    Nov 1, 2010, 00:00

  • PMH7 FACTORS ASSOCIATED WITH TOTAL TIME AND COST OF PROVIDING CARE FOR THAI PATIENTS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • PDB18 THE PREVALENCE AND IMPACT OF BEING AT-RISK FOR DIABETES ACROSS US, JAPAN, AND EUROPE

    Nov 1, 2010, 00:00

  • PSS17 ECONOMIC EVALUATION OF A 100-WHEY BASED PARTIALLY HYDROLYZED FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG DANISH CHILDREN- PRELIMINARY ANALYSES

    Nov 1, 2010, 00:00

  • PCV20 GENERALIZED COST-EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL INTERVENTIONS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN THAILAND

    Nov 1, 2010, 00:00

  • PMS36 COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN COSTA RICA

    Nov 1, 2010, 00:00

  • PIN43 A COST-EFFECTIVENESS ANALYSIS OF ANTIMICROBIAL THERAPY OF BLOODSTREAM INFECTIONS TREATMENT IN INTENSIVE CARE UNIT

    Nov 1, 2010, 00:00

  • PSY45 PREGABALIN IS A COST-EFFECTIVE MEDICINE FOR REFRACTORY NEUROPATHIC PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PND45 MANAGEMENT OF DRUG RESISTANT EPILEPSIES- HTA REPORT FOR THREE ITALIAN REGIONS

    Nov 1, 2010, 00:00

  • PRS17 COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE-A HEALTH CARE ADMINISTRATIVE DATABASES ANALYSIS

    Nov 1, 2010, 00:00

  • PCN79 ECONOMIC MODELING FOR TREATMENT FAILURE PATIENTS USING MULTIPLE ROUNDS OF THERAPY AS COMPARATOR

    Nov 1, 2010, 00:00

  • PIH31 STATIC AND DYNAMIC BALANCE EXAMINATION ON STABILOMETER DURING PREGNANCY

    Nov 1, 2010, 00:00

  • PSY37 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF OROS HYDROMORPHONE IN PATIENTS WITH CHRONIC CANCER PAIN FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PSY33 EARLY STAGE ECONOMIC EVALUATION OF PHARMACOGENOMICBASED DIAGNOSTICS IN CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PND40 QUALITY OF LIFE OF CAREGIVERS IN HUNTINGTONS DISEASE-FIRST RESULTS FROM EURO-HDB STUDY

    Nov 1, 2010, 00:00

  • PMH53 FACTOR STRUCTURE OF A SOCIAL SUPPORT SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER

    Nov 1, 2010, 00:00

  • PIN12 PSEUDOMONAS AERUGINOSA RELATED BURDEN ON CYSTIC FIBROSIS PATIENTS- COMPARING HEALTH CARE COSTS AND RESOURCE UTILIZATION ACROSS AGE GROUPS

    Nov 1, 2010, 00:00

  • PCV18 ECONOMIC EVALUATION OF USING HIGH-DOSE ATORVASTATIN FOR THE PREVENTION OF RECURRENT STROKE- EVIDENCE FROM THAILAND

    Nov 1, 2010, 00:00

  • PMH2 COMPARING ALL-CAUSE MEDICATION DISCONTINUATION WITH DEPOT AND ORAL ANTIPSYCHOTICS IN MATCHED COHORTS OF PATIENTS WITH SCHIZOPHRENIA- A 12-MONTH OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PMC50 TRANSLATION, LINGUISTIC VALIDATION AND ELECTRONIC ADMINISTRATION IN THE INDIAN LANGUAGES- A CASE STUDY HIGHLIGHTING THE SPECIAL DIFFICULTIES THAT EXIST AT THIS INTERSECTION

    Nov 1, 2010, 00:00

  • BI1 ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER

    Nov 1, 2010, 00:00

  • PCV66 ECONOMIC PERFORMANCE OF DABIGATRAN ETEXILATE FOR PRIMARY VTE PREVENTION FOLLOWING TOTAL HIP AND KNEE REPLACEMENT SURGERY IN ITALY

    Nov 1, 2010, 00:00

  • PIN9 EFFICACY AND SAFETY OF RALTEGRAVIR IN TREATMENT NAIVE HIV PATIENTS-A MIXED TREATMENT COMPARISON APPROACH

    Nov 1, 2010, 00:00

  • PCN8 IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PDB10 PREVALENCE AND OUTCOME OF INSULIN ANALOGUE TREATMENT COMPARING GERMANY, UK, AND FRANCE

    Nov 1, 2010, 00:00

  • PSS24 QUALITY OF LIFE IN OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • CV4 THE CLINICAL EFFECTIVENESS OF 64-SLICE OR HIGHER COMPUTED TOMOGRAPHY ANGIOGRAPHY AS AN ALTERNATIVE TO INVASIVE CORONARY ANGIOGRAPHY IN THE INVESTIGATION OF SUSPECTED CORONARY ARTERY DISEASE

    Nov 1, 2010, 00:00

  • PCV73 ECOMOMIC EVALUATION OF COMBINATION THERAPY FOR HYPERTENSION IN HIGH RISK PATIENTS IN SWEDEN

    Nov 1, 2010, 00:00

  • PMH60 QUALITY- A NON-INTERVENTIONAL STUDY EVALUATING QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS, IN THE AMBULATORY SETTING. A 9-MONTH, OBSERVATIONAL, MULTICENTRIC PROSPECTIVE STUDY

    Nov 1, 2010, 00:00

  • PCV69 COST-EFFECTIVENESS OF EPLERENONE COMPARED WITH SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2010, 00:00

  • PIN15 COST-EFFECTIVENESS ANALYSIS OF 1-YEAR PEGINTERFERON ALFA-2A VERSUS 3 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

    Nov 1, 2010, 00:00

  • PSY53 ORGANIZATION OF ACUTE PAIN SERVICE (APS) IN THE HUNGARIAN HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PSY51 STATED PREFERENCES OF PHYSICIANS AND CHRONIC PAIN SUFFERERS IN THE USE OF CLASSICAL STRONG OPIOIDS

    Nov 1, 2010, 00:00

  • PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB

    Nov 1, 2010, 00:00

  • PCN98 COST-EFFECTIVENESS OF A EUROPEAN COMMUNITY-BASED INTERVENTION- '10,000 STEPS GHENT'

    Nov 1, 2010, 00:00

  • PCN109 COMPARISON OF HOSPITALIZATION BURDEN BETWEEN METASTATIC AND NON-METASTATIC MELANOMA PATIENTS IN A US POPULATION

    Nov 1, 2010, 00:00

  • PSY12 REAL-LIFE BUDGET IMPACT (BI) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANEMIA/SYNDROME (IDA/IDS) IN SWITZERLAND

    Nov 1, 2010, 00:00

  • PMH51 HEALTH STATUS AND COST OF CARE IN PATIENTS WITH DEMENTIA IN GERMANY

    Nov 1, 2010, 00:00

  • PMH70 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE ALCOHOL DEPENDENCE SCALE

    Nov 1, 2010, 00:00

  • PHP38 HOW EQUITABLE OF HEALTH SERVICE USE AND GOVERNMENT SUBSIDIES IN THAILAND AFTER ACHIEVING UNIVERSAL COVERAGE?

    Nov 1, 2010, 00:00

  • PCV52 COST OF MANAGING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION TO MANAGED CARE

    Nov 1, 2010, 00:00

  • PDB16 INSULIN GLARGINE IS ASSOCIATED WITH A LOWER INCIDENCE OF DIABETIC FOOT SYNDROME AND MACROVASCULAR COMPLICATIONS COMPARED TO NPH INSULIN IN TYPE 2 DIABETICS UNDER GERMAN REAL-LIFE CONDITIONS

    Nov 1, 2010, 00:00

  • PIN24 IMPACT OF APPROPRIATE PRESCRIBING OF ANTIBIOTICS ON TREATMENT OUTCOMES, DAYS OF PATIENT HOSPITALIZATION AND COSTS OF ANTIBIOTIC TREATMENT IN HOSPITALS IN LESOTHO

    Nov 1, 2010, 00:00

  • PHP97 TRAINING OF PHARMACEUTICAL SALES REPRESENTATIVES IN REGARD TO CHANGES IN HEALTH CARE POLICY IN GERMANY

    Nov 1, 2010, 00:00

  • PSS26 REVIEW OF UTILITIES IN ATOPIC DERMATITIS

    Nov 1, 2010, 00:00

  • PIH2 IMPACT OF HPV VACCINATION ON CERVICAL CANCER IN ASIA- RESULTS OF A STATIC MODEL

    Nov 1, 2010, 00:00

  • PMC14 DISCOUNTING HEALTH EFFECTS- A REVIEW OF THE SYSTEM

    Nov 1, 2010, 00:00

  • PMH65 EFFECTIVENESS OF PHARMACEUTICAL THERAPY OF ADHD (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER) IN ADULTS-A HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2010, 00:00

  • PUK10 GENERIC AZATHIOPRIN FOR KYDNEY TRANSPLANT PATIENTS-ANALYSIS OF COST SAVINGS

    Nov 1, 2010, 00:00

  • PRS9 DRUG UTILIZATION EVALUATION OF COMBINED INHALER THERAPIES AMONG PATIENTS WITH AIRWAY DISEASES IN A 2000-BED MEDICAL CENTER IN TAIWAN

    Nov 1, 2010, 00:00

  • PIN28 IMPACT OF METHODOLOGICAL CHOICES AND ASSUMPTIONS IN ECONOMIC EVALUATIONS OF ROTAVIRUS VACCINATION

    Nov 1, 2010, 00:00

  • PND31 IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS INTERFERON -1A FOR MULTIPLE SCLEROSIS PATIENTS USING A MAIL-ORDER PHARMACY

    Nov 1, 2010, 00:00

  • PND34 A PSYCHOMETRIC EVALUATION OF THE REVISED SCOPA DIARY CARD IN PARKINSONS DISEASE PATIENTS

    Nov 1, 2010, 00:00

  • PCN1 TOLERABILITY OF FIRST-LINE TREATMENTS OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC)-A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

    Nov 1, 2010, 00:00

  • PUK30 MAPPING THE OVERACTIVE BLADDER QUESTIONNAIRE-SHORT FORM (OABQ-SF) TO EQ-5D PATIENT PREFERENCES IN PATIENTS WITH OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2010, 00:00

  • PHP22 THE USE OF ECONOMIC EVALUATIONS IN DECISION-MAKING AT MACRO LEVEL- A LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PCN86 COST-EFFECTIVENESS ANALYSIS OF SPLANCHNIC NERVE BLOCKADE IN PATIENTS WITH CANCER AND VISCERAL PAIN IN THE UPPER ABDOMEN

    Nov 1, 2010, 00:00

  • PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE

    Nov 1, 2010, 00:00

  • PCV129 TELEHEALTH-EARLY EVALUATION FINDINGS

    Nov 1, 2010, 00:00

  • PSY38 COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS FROM THE UK PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PGI19 PRESCRIPTION RATES AND ADHERENCE TO PROTON PUMP INHIBITOR THERAPY AMONG PATIENTS WHO REQUIRE LOW-DOSE ACETYLSALICYLIC ACID FOR CARDIOVASCULAR PREVENTION

    Nov 1, 2010, 00:00

  • PCV95 ECONOMIC EVALUATION OF LIFESTYLE INTERVENTION IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN 60-YEAR-OLD MEN IN STOCKHOLM, SWEDEN

    Nov 1, 2010, 00:00

  • PIH52 EVALUATING THE PERCEPTION OF HOSPITAL PHARMACIST TOWARD THEIR CURRENT CLINICAL ROLE IN HEALTH CARE SYSTEM OF PAKISTAN

    Nov 1, 2010, 00:00

  • PCV56 RENAL MORBIDITY, MORTALITY, AND COSTS IN INDIVIDUALS UNDERGOING INVASIVE CARDIAC CATHETERIZATION PROCEDURES WITH LOW-OSMOLAR CONTRAST MEDIA-A LARGE RETROSPECTIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PHP132 VALUE OF MULTI-CRITERIA DECISION ANALYSIS IN EARLY ASSESSMENT OF MEDICAL DIAGNOSTIC DEVICES

    Nov 1, 2010, 00:00

  • PMC48 UPDATES AND INNOVATIONS IN ELECTRONIC PATIENT-REPORTED DATA CAPTURE-A REVIEW OF THE EVOLUTION AND FUTURE DIRECTIONS OF EPRO

    Nov 1, 2010, 00:00

  • PCV41 COST COMPARISON STUDY IN ACUTE CORONARY SYNDROMES AND ACUTE HEART FAILURE PATIENTS

    Nov 1, 2010, 00:00

  • PMS53 QUALITY OF LIFE, PATIENTS PREFERENCES AND INFORMED DECISION IN TREATING RHEUMATOID ARTHRITIS IN GREECE

    Nov 1, 2010, 00:00

  • PSY1 DEVELOPMENT OF A CO-MORBIDITY SCALE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PCV25 PATTERN OF LIPID MODIFYING AGENTS PRESCRIPTION AMONG CLUSTERS OF PHYSICIAN IN A THAI TEACHING HOSPITAL, FISCAL YEAR 2009

    Nov 1, 2010, 00:00

  • PCN24 EFFICACY OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE (GEM) COMPARED TO SURGERY-ONLY IN PATIENTS WITH RESECTED PANCREATIC CANCER- SYSTEMATIC REVIEW (SR) AND METAANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PMH15 THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM PATIENTS PERSPECTIVES

    Nov 1, 2010, 00:00

  • PGI22 MAPPING PAC-QOL SCORES ONTO THE EQ-5D

    Nov 1, 2010, 00:00

  • PND16 MODELING THE CLINICAL AND ECONOMIC IMPLICATIONS OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE IN GERMANY

    Nov 1, 2010, 00:00

  • PRS41 FACTORS AFFECTING QUALITY OF LIFE (QOL) OF ASTHMATIC PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PCN58 SURVEY AND ANALYSIS OF THE COSTS OF METASTATIC COLORECTAL CANCER TREATMENT IN BULGARIA

    Nov 1, 2010, 00:00

  • PCN140 IMPROVING PATIENT ACCESS TO CANCER DRUGS IN INDIA- USING ECONOMIC MODELING TO ESTIMATE A DRUG COST BASED ON MEASURES OF SOCIETAL VALUE

    Nov 1, 2010, 00:00

  • PHP90 THE EFFECT OF THE 2007 HOSPITAL REFORM ON THE NUMBER OF PSYCHIATRIC BEDS IN HUNGARY

    Nov 1, 2010, 00:00

  • PDB13 DIAPS 79, PRELIMINARY REPORT OF AN OBSERVATIONAL STUDY OF COSTS OF TYPE 2 DIABETES MELLITUS (T2DM) TREATMENT IN THE BRAZILIAN PRIVATE HEALTH-CARE SYSTEM (PHS)

    Nov 1, 2010, 00:00

  • PMH26 COST ANALYSIS OF METHADONE MAINTENANCE THERAPY (MMT) PROGRAM IN MALAYSIA

    Nov 1, 2010, 00:00

  • PMC6 ASSESSING PRODUCTIVITY AND ACTIVITY IMPAIRMENT DUE TO ILLNESS IN POLAND

    Nov 1, 2010, 00:00

  • PCV85 PRASUGREL VS. CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION- A SPANISH MODEL-BASED COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PGI31 EVALUATING THE POST OPERATIVE PRESCRIBING PRACTICES FOR APPENDICITIS IN PUBLIC HEALTH FACILITIES IN PAKISTAN

    Nov 1, 2010, 00:00

  • PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2010, 00:00

  • PMS72 INTERACTIVE ELECTRONIC INTERFACES (IEI)- BRIDGING THE COMMUNICATION GAP BY TRANSLATING ECONOMIC ANALYSIS RESULTS TO DECISION-MAKERS EVERYDAY PRACTICE

    Nov 1, 2010, 00:00

  • PMH46 ADHERENCE RATES OF INJECTABLE VS. ORAL RISPERIDONE FOR PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PND9 ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY OF 100 PATIENTS

    Nov 1, 2010, 00:00

  • PR4 GLOBAL MARKET ACCESS STRATEGY-AN INTEGRATED APPROACH

    Nov 1, 2010, 00:00

  • PCV4 CLINICAL AND COST OUTCOMES OF VENOUS THROMBOEMBOLISM IN PATIENTS WHO UNDERWENT MAJOR ORTHOPEDIC SURGERY

    Nov 1, 2010, 00:00

  • PCN19 SYSTEMATIC REVIEW OF ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR EARLY GASTRIC CANCER

    Nov 1, 2010, 00:00

  • PRS4 EFFECTIVENESS OF VARENICLINE COMPARED TO BUPROPION AND NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN TWO SMOKING SPECIALIZED UNITS OF THE SPANISH PRIMARY CARE SETTING

    Nov 1, 2010, 00:00

  • PMC27 VALUES FOR HEALTH STATES UNDER DIFFERENT LIFE DURATIONS

    Nov 1, 2010, 00:00

  • PCN162 EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING- IN SEARCH OF A STANDARD

    Nov 1, 2010, 00:00

  • PSY66 WEB VERSUS FACE-TO-FACE (FTF) ADMINISTRATION OF A HEALTH UTILITY SURVEY IN THE GENERAL PUBLIC- RESULTS FROM A TIME TRADE-OFF (TTO) SURVEY ON IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

    Nov 1, 2010, 00:00

  • PMH41 COST-UTILITY ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN MAJOR DEPRESSIVE DISORDER IN ISRAEL

    Nov 1, 2010, 00:00

  • PMH5 ESTABLISHING THE COMPARATIVE EFFICACY OF ALZHEIMERS DISEASE THERAPY THROUGH SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS

    Nov 1, 2010, 00:00

  • PHP63 THE ECONOMIC IMPACT OF THE INITIATION OF PRESCRIPTION CONTROL IN THE GREEK SOCIAL SECURITY FUNDS

    Nov 1, 2010, 00:00

  • PCV14 COSTS OF INITIAL ISCHEMIC STROKE CARE

    Nov 1, 2010, 00:00

  • PCN22 EFFICACY AND CARDIAC SAFETY OF TRASTUZUMAB (T) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY-STAGE BREAST CANCER- A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Nov 1, 2010, 00:00

  • PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) IN ...

    Nov 1, 2010, 00:00

  • PND29 COST-UTILITY ANALYSIS OF RIZATRIPTAN VERSUS (GENERIC) SUMATRIPTAN IN SWEDEN

    Nov 1, 2010, 00:00

  • HE4 THE EFFECT OF PRICE CONTAINMENT ON THE TREND OF PHARMACEUTICAL EXPENDITURE FROM 1999 TO 2007 IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV1 ESTIMATION OF STROKE-RELATED ADVERSE EVENTS, HEALTH CARE UTILITY AND COST OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Nov 1, 2010, 00:00

  • AD1 SHORT MESSAGE SERVICE (SMS)-BASED STRATEGY TO IMPROVE ANTIPSYCHOTIC ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PCV44 ROLE OF COMMUNITY PHARMACISTS IN HEALTH-RELATED EDUCATION AND COUNSELLING-VIEWS FROM GENERAL PUBLIC IN THE STATE OF PENANG, MALAYSIA

    Nov 1, 2010, 00:00

  • PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PIH20 EXPLORATORY COST-EFFECTIVENESS ANALYSIS OF THE ANTERIOR REPAIR OF THE PELVIC ORGAN PROLAPSE COMPARING ANTERIOR COLPORRHAPHY (CONVETIONAL SURGERY) VERSUS PROLIFT MESH, UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PUK32 CONTENT VALIDITY OF A PATIENT-REPORTED URINARY URGENCY RATING SCALE- RESULTS OF A COGNITIVE INTERVIEW STUDY

    Nov 1, 2010, 00:00

  • PCN80 COST-EFFECTIVENESS ANALYSIS OF OXLIPLATIN IN ADJUVANT THERAPY FOR STAGE 3 COLON CANCER PATIENTS IN JAPAN

    Nov 1, 2010, 00:00

  • PMS69 ECONOMY OF NSAIDS IN THE MANAGEMENT OF OSTEOARTHRITIS- SODIUM CHONDROITIN SULFATE VS. CONTROL GROUP

    Nov 1, 2010, 00:00

  • CE2 COST-UTILITY ANALYSIS OF INTENSIVE LIFESTYLE INTERVENTIONS OR METFORMIN VERSUS STANDARD CARE IN THE PREVENTION OF TYPE 2 DIABETES IN HIGH-RISK SUBJECTS IN AN AUSTRALIAN SETTING. A SIMULATION ANALYSIS BASED ON THE LONG-TERM RESULTS OF TH ...

    Nov 1, 2010, 00:00

  • PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PMH18 THE EFFECT OF DIAGNOSED, SELF-REPORTED, AND AT-RISK DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN JAPAN AND EUROPE

    Nov 1, 2010, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF A FOBT-BASED COLORECTAL CANCER SCREENING PROGRAM

    Nov 1, 2010, 00:00

  • PRS8 THE EFFECT OF UNCONTROLLED ASTHMA ON HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN JAPAN AND THE UNITED STATES

    Nov 1, 2010, 00:00

  • PND46 NON-LOCAL PATIENT-LEVEL DATA FOR COST-EFFECTIVENESS ADAPTATION TO THE SWEDISH ENVIRONMENT

    Nov 1, 2010, 00:00

  • PHP28 IMPACT OF SAFETY ISSUESS BUDGET

    Nov 1, 2010, 00:00

  • PUK28 THE ECONOMIC BURDEN OF POST-TRANSPLANT EVENTS IN RENAL TRANSPLANT PATIENTS (PORTRAIT STUDY) IN A SINGLE UK CENTRE

    Nov 1, 2010, 00:00

  • PMH22 HEALTH SCIENCE STUDENTS ATTITUDES TOWARD RESEARCH AND ITS IMPLICATIONS TO TEACHING

    Nov 1, 2010, 00:00

  • PGI17 COULD AN INNOVATIVE SURGICAL PROCEDURE SUCH AS STAPLED HEMORRHOIDOPEXY BE COST-EFFECTIVE AND EVEN COST-SAVING IN UK CLINICAL PRACTICE?

    Nov 1, 2010, 00:00

  • BL3 A CONCEPTUAL MODEL FOR POMPE DISEASE-THE BACKBONE FOR AN ECONOMIC EVALUATION OF AN ORPHAN DRUG

    Nov 1, 2010, 00:00

  • PCV86 ECONOMIC EVALUATION OF DRONEDARONE IN TREATMENT OF ATRIAL FIBRILLATION IN GREECE

    Nov 1, 2010, 00:00

  • PMC40 ITEM CALIBRATION OF A GENERIC ROLE FUNCTIONING ITEM BANK

    Nov 1, 2010, 00:00

  • PMS4 BURDEN OF DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA- RESULTS FROM 2009 NATIONAL HEALTH AND WELLNESS SURVEY

    Nov 1, 2010, 00:00

  • PCV84 ECONOMIC EVALUATION OF IMPLANTABLE LOOP RECORDER IN THE DIAGNOSIS OF SYNCOPE, UPDATE FROM THE SPANISH NATIONAL HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PMS9 TREND OF HIP FRACTURE INCIDENCE IN BELGIUM BETWEEN 2000 AND 2007 AND FUTURE PROJECTIONS

    Nov 1, 2010, 00:00

  • PRS7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF CICLESONIDE WITH FLUTICASONE IN 1-1 AND 1-2 DOSE RATIOS IN THE TREATMENT OF BRONCHIAL ASTHMA

    Nov 1, 2010, 00:00

  • PSY15 CONSTIPATION RELATED TO OPIOID THERAPY-A COST-OF-ILLNESS AND PREVALENCE DATABASE STUDY IN THE BRAZILIAN PRIVATE SETTING

    Nov 1, 2010, 00:00

  • PND23 COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/ ENTACAPONE IN TREATMENT OF PARKINSON DISEASE

    Nov 1, 2010, 00:00

  • PDB77 QUALITY OF TREATMENT OF DIABETES MELLITUS TYPE 2 IN THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PSY56 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)- UNDERSTANDING THE BURDEN

    Nov 1, 2010, 00:00

  • PIN8 CLINICAL EFFECTIVENESS OF THE SEASONAL INFLUENZA VACCINE IN HEALTHY INDIAN CHILDREN

    Nov 1, 2010, 00:00

  • PHP104 DESIGNING EUROPEAN GUIDELINES FOR HEALTH OUTCOMES AND COST-EFFECTIVENESS ASSESSMENTS-THE ECHOUTCOME EUROPEAN COMMISSION PROJECT

    Nov 1, 2010, 00:00

  • PGI28 HEALTH-RELATED QUALITY OF LIFE IN OPIOID INDUCED CONSTIPATION PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PCV49 THE EVALUATION OF CARE PATHWAYS AS A COMPLEX INTERVENTION- APPLICATION OF A METHODOLOGICAL FRAMEWORK

    Nov 1, 2010, 00:00

  • MO4 USING AHP WEIGHTS TO FILL MISSING GAPS IN MARKOV DECISION MODELS

    Nov 1, 2010, 00:00

  • PMS61 RELATING OSTEOARTHRITIS AFFECTATION, FUNCTIONAL DISABILITY AND QUALITY OF LIFE-A STRUCTURAL EQUATION MODEL. THE EXPECT STUDY

    Nov 1, 2010, 00:00

  • PCN38 INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO BIOSIMILARS

    Nov 1, 2010, 00:00

  • PIH28 WHY DO PATIENTS NOT ADHERE TO PRESCRIBED MEDICATION REGIMES? RESULTS OF TWO GERMAN SURVEYS

    Nov 1, 2010, 00:00

  • PCN35 PRIMARY HEPATOCELLULAR CARCINOMA PATIENTS REPEATED MEDICAL UTILIZATION AND EXPENDITURE FOR CONFIRMATION IN TAIWAN

    Nov 1, 2010, 00:00

  • PIH32 TREATMENTS TO PREVENT PROSTATE CANCER AND THEIR IMPACT ON HEALTH RELATED QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PCN70 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN BRAZIL

    Nov 1, 2010, 00:00

  • PMH22 RESULTS OF THE GERMAN IDA STUDY-ASSESSING THE FINANCIAL IMPACT OF INFORMAL CARE AMONGST COMMUNITY LIVING DEMENTIA PATIENTS

    Nov 1, 2010, 00:00

  • PDB9 LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 DIABETES PROJECTED USING THE CORE DIABETES MODEL

    Nov 1, 2010, 00:00

  • PIH41 USE OF QUALITATIVE RESEARCH TO IDENTIFY DETERMINANTS OF PERSISTENCE FOR ANTI-OSTEOPOROTIC TREATMENTS

    Nov 1, 2010, 00:00

  • PCN41 ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING

    Nov 1, 2010, 00:00

  • PCV120 COMBINED MEDICATION CHOICE AND PATIENT PERSISTENCE IN HYPERTENSION THERAPY- EVIDENCE OF REAL-LIFE EFFECTIVENESS

    Nov 1, 2010, 00:00

  • PHP70 CURRENT TRENDS IN HEALTH TECHNOLOGY INCORPORATION (HTI) IN BRAZIL- INSIDE THE NATIONAL HEALTH SYSTEMS (NHS) BLACK BOX

    Nov 1, 2010, 00:00

  • PIN10 COST VERSUS DRG REVENUE IMPLICATIONS OF TREATING A PATIENT WITH VENTILATOR-ASSOCIATED PNEUMONIA (VAP) WITH DORIPENEM VERSUS IMIPENEM IN GERMANY

    Nov 1, 2010, 00:00

  • PIH44 THE INFLUENCE OF INDIVIDUAL FACTORS ON PELVIC PAIN AND QUALITY OF LIFE IN ENDOMETRIOSIS

    Nov 1, 2010, 00:00

  • HE3 ANALYSIS OF AN AFFORDABLE PRICE FOR PERFORMANCE-BASED RISK SHARING SCHEME- OMALIZUMAB ADAPTATION IN KOREA

    Nov 1, 2010, 00:00

  • PSS3 THE ECONOMIC BURDENS FOR PATIENTS WITH PSORIASIS IN TAIWAN

    Nov 1, 2010, 00:00

  • PIN22 ECONOMIC EVALUATION OF THREE-DRUG ANTIRETROVIRAL REGIMENS FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN THAILAND

    Nov 1, 2010, 00:00

  • PSS15 COST-EFFECTIVENESS OF USTEKINUMAB VS. INFLIXIMAB FOR SEVERE PSORIASIS

    Nov 1, 2010, 00:00

  • PIH1 CRITICAL APPRAISAL OF SYSTEMATIC REVIEWS ASSESSING SAFETY OUTCOMES OF SSRIS IN THE PERINATAL PERIOD

    Nov 1, 2010, 00:00

  • PCV13 CAN WE REDUCE COST OF ILLNESS WITH MORE COMPLIANT PATIENTS? THE ESTIMATION OF EFFECT OF 100 COMPLIANT TO TREATMENTS OF DIABETES AND HYPERTENSION

    Nov 1, 2010, 00:00

  • PHP8 DRUG USE PATTERN IN OVER 60-YEAR-OLD POPULATION OF TEHRAN IN 2007 IRAN

    Nov 1, 2010, 00:00

  • PHP133 PERSONALIZED PHARMACOTHERAPY AND ANALYSIS OF EXTEMPORANEOUS DOSAGE FORMS FOR CHILDREN IN UKRAINE

    Nov 1, 2010, 00:00

  • PIN21 EMPIRIC ANTIBIOTIC PRRESCRIBING IN SUBJECTS WITH INFLUENZA IN A UNITED STATES COMMERCIALLY INSURED POPULATION

    Nov 1, 2010, 00:00

  • PCN33 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA- A GENERAL POPULATION STUDY

    Nov 1, 2010, 00:00

  • PMC26 EXAMINATION OF TYPE I AND II ERROR RATES IN INTENTION-TOTREAT RANDOMIZED EXPERIMENTS- DO SUBJECTS NEED TO STAY IN THE GROUP IN WHICH THEY WERE ASSIGNED?

    Nov 1, 2010, 00:00

  • PIH4 COST OF PUBLIC HEALTH DELIVERY OF CHILDHOOD IMMUNIZATIONS IN NOVA SCOTIA

    Nov 1, 2010, 00:00

  • PCN85 SORAFENIB AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA- COST-EFFECTIVENESS ANALYSIS IN REIMBURSEMENT PROCEEDINGS VS. DATA FROM CLINICAL PRACTICE

    Nov 1, 2010, 00:00

  • PUK14 HEALTH CARE COST OF RENAL REPLACEMENT THERAPY IN HUNGARY

    Nov 1, 2010, 00:00

  • PHP17 MEASURING MEDICATION RECONCILIATIONS IMPACT ON THE FINANCIAL COST

    Nov 1, 2010, 00:00

  • PCV19 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP AND KNEE REPLACEMENT (THR, TKR) IN CHINESE PATIENTS

    Nov 1, 2010, 00:00

  • PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN

    Nov 1, 2010, 00:00

  • PHP67 HAS THE QUALITY AND OUTCOMES FRAMEWORK INFLUENCED PRIMARY CARE DATA RECORDING?

    Nov 1, 2010, 00:00

  • PMS32 MICRO-COSTING ANALYSIS AND TARIFF COMPARISON- THE INTERSPINOUS PROCESS DEVICE CASE

    Nov 1, 2010, 00:00

  • PDB3 EFFECTS OF EXTENDED-RELEASE VERSUS IMMEDIATE-RELEASE GLIPIZIDES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PHP131 THE USE OF ECONOMIC EVALUATION IN A MEDICAL DEVICE COMMISION OF AN ITALIAN TEACHING HOSPITAL

    Nov 1, 2010, 00:00

  • PCN105 COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Nov 1, 2010, 00:00

  • PCV39 CLINICAL OUTCOMES AND COSTS OF A POCKET-SIZED ULTRASOUND DEVICE FOR SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN ITALY

    Nov 1, 2010, 00:00

  • PDB25 RELATIONSHIPS OF QUALITY OF LIFE AND COSTS WITH CLINICAL CHARACTERISTICS OF DIABETES PATIENTS

    Nov 1, 2010, 00:00

  • PDB29 STATUS AND TREATMENT OF TYPE 2 DIABETES IN CHINA

    Nov 1, 2010, 00:00

  • PCN30 ESTIMATING WOMENS PREFERENCES FOR CERVICAL CANCER SCREENING PROGRAMS USING CONJOINT ANALYSIS

    Nov 1, 2010, 00:00

  • PGI23 IDENTIFYING ENDPOINTS FOR IRRITABLE BOWEL SYNDROME (IBS) CLINICAL TRIALS- INCORPORATING THE PATIENTS VOICE

    Nov 1, 2010, 00:00

  • PSY63 WORK AND DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH DIGITAL ULCERS (DUS)-RESULTS FROM THE DUO REGISTRY

    Nov 1, 2010, 00:00

  • PCV21 THE RELATIVE EFFECTIVENESS PROFILE OF DRONEDARONE USING THE NUMBER NEEDED TO TREAT (NNT) APPROACH

    Nov 1, 2010, 00:00

  • PUK6 EVALUATION OF PSYCHOMETRIC PROPERTIES OF THE JAPANESE VERSION OF THE NOCTURIA QUALITY OF LIFE QUASTIONNAIRE (N-QOL)

    Nov 1, 2010, 00:00

  • PCV32 COST-EFFECTIVENESS ANALYSIS OF DISEASE MANAGEMENT PROGRAM OF HYPERTENSION IN SHANGHAI, CHINA

    Nov 1, 2010, 00:00

  • PSY39 REAL-WORLD COST-EFFECTIVENESS OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PMH36 ECONOMIC EVALUATION ANALYSIS IN THE TREATMENT OF BIPOLAR DISORDER WITH ARIPIPRAZOLE AND OTHER ATYPICAL ANTIPSYCHOTIC DRUGS IN SPAIN

    Nov 1, 2010, 00:00

  • IR1 METHODS FOR PSYCHOMETRIC AND CLINICAL EVALUATIONS OF CAT-BASED MEASURES OF DISEASE IMPACT IN CHRONIC KIDNEY DISEASE (CKD)

    Nov 1, 2010, 00:00

  • CV2 ATTRIBUTABLE COST AND LENGTH OF STAY FOR PATIENTS WITH ENOXAPARIN-ASSOCIATED BLEEDING

    Nov 1, 2010, 00:00

  • PHP54 BUDGET IMPACT OF ORPHAN DRUGS IN DENMARK COMPARED TO OTHER EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • EQ2 TESTING THE PERFORMANCE OF THE NEWLY DEVELOPED VERSION OF THE EQ-5D WITH 5 LEVELS OF SEVERITY- APPLICATION ON A COHORT OF PATIENTS WITH CHRONIC HEPATIC DISEASES

    Nov 1, 2010, 00:00

  • PMC38 A COGNITIVE DEBRIEFING METHODOLOGY FOR ESTABLISHING EQUIVALENCE DURING E-PRO MIGRATION

    Nov 1, 2010, 00:00

  • PGI3 EFFECTIVENESS AND COST ANALYSIS OF PARENTERNAL REGIMEN IN CRITICAL ILLNESS PATIENTS OF POSTOPERATIVE-THREE COMPARTMENT BAG SYSTEM AND TRANDITIONAL SEPARATE BOTTLE SYSTEM

    Nov 1, 2010, 00:00

  • PIH26 MEDICATION CHECKUPS BY COMMUNITY PHARMACISTS- EXPERIENCE OF 'BROWN-BAG' REVIEWS IN JAPAN

    Nov 1, 2010, 00:00

  • PCN119 COMPARISON OF EQ-5D SCORE BETWEEN TREATMENT WITH 4 CYCLES OF ANTHRACYCLINE FOLLOWED BY 4 CYCLES OF TAXANE AND 8 CYCLES OF TAXANE FOR NODE POSITIVE BREAST CANCER PATIENTS AFTER SURGERY- N-SAS BC 02 TRIAL

    Nov 1, 2010, 00:00

  • PDB83 TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2010, 00:00

  • PCN36 COST IMPLICATIONS OF RESTRICTING PALONOSETRON UTILIZATION FOR THE TREATMENT OF CINV- RESULTS FROM AN ANALYTIC MODEL FROM A PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • MA4 ANCHOR-BASED DETERMINATION OF THE MINIMAL IMPORTANT DIFFERENCE OF A PRO SCALE-A CRITICAL LOOK ON A WIDELY USED METHOD BY MEANS OF A SIMULATION STUDY

    Nov 1, 2010, 00:00

  • PND32 INFLUENCE OF AGE ON REFILL-ADHERENCE RATES OF ANTIEPILEPTIC DRUGS IN SOUTH AFRICA

    Nov 1, 2010, 00:00

  • IN1 ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES AND ACUTE OTITIS MEDIA IN TAIWAN- A NATIONWIDE POPULATION-BASED DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PCV46 COST STUDY OF CAREGIVING FOR PATIENTS WITH CHRONIC SYMPTOMATIC HEART FAILURE IN SPAIN

    Nov 1, 2010, 00:00

  • PCV48 COST-OF-ILLNESS AND HEALTH-RELATED QUALITY OF LIFE IN SUBARACHNOID HEMORRHAGE- GERMAN LONGITUDINAL STUDY

    Nov 1, 2010, 00:00

  • PSY5 COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG-AN INITIAL ANALYSIS

    Nov 1, 2010, 00:00

  • PMC13 METHODS AND IMPACT OF INCORPORATING MEDICATION COMPLIANCE INTO PHARMACOECONOMIC EVALUATIONS

    Nov 1, 2010, 00:00

  • PND24 THE IMPACT OF COHORT SELECTION ON COST-EFFECTIVENESS RESULTS IN MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PCV80 THE COST-EFFECTIVENESS OF AMLODIPINE BESYLATE VERSUS PLACEBO FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA

    Nov 1, 2010, 00:00

  • PCN56 CLINICO-ECONOMIC ANALYSIS OF TREATMENT OF CHILDREN WITH RHABDOMYOSARCOMAS ON PROTOCOLS CWS

    Nov 1, 2010, 00:00

  • PCN27 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER THE 200-2015 PERIOD IN PORTUGAL

    Nov 1, 2010, 00:00

  • PMC7 TARIFF LISTS FROM SPANISH AUTONOMOUS COMMUNITIES- AN ASSESSMENT OF ITS STRUCTURE, CONTENTS, AND TARIFF LEVELS

    Nov 1, 2010, 00:00

  • PHP40 REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL- CITEC SUBMISSIONS PROFILE

    Nov 1, 2010, 00:00

  • IN3 ASSESSMENT OF KNOWLEDGE ABOUT TUBERCULOSIS AMONG LIBYAN POPULATION IN NORTH EAST LIBYA

    Nov 1, 2010, 00:00

  • MT2 CONDUCTING A MIXED TREATMENT COMPARISON (MTC) IN A SPECIFIC POPULATION- POSTMENOPAUSAL WOMEN WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER WHICH OVEREXPRESSES HER2

    Nov 1, 2010, 00:00

  • PHP51 ROUTINE REPLACEMENT OF PERIPHERAL INTRAVENOUS CATHETER VERSUS CLINICALLY INDICATED REPLACEMENT- A COST COMPARISON STUDY FROM THE PUBLIC PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PMC34 ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF CAREGIVER RATING SCALES REGARDING THE BEHAVIOR AND DEVELOPMENT OF CHILDREN AND YOUNG PEOPLE

    Nov 1, 2010, 00:00

  • PSY48 RESOURCE USE AND COSTS OF THE GASTRIC BYPASS SURGERY VERSUS CLINICAL TREATMENT FOR OBESE PATIENTS WITH COMORBIDITIES UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

    Nov 1, 2010, 00:00

  • PIN18 COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL NEWBORN VACCINATION AGAINST HEPATITIS B VIRUS IN VIETNAM

    Nov 1, 2010, 00:00

  • PIH43 USE OF QUALITY-ADJUSTED LIFE-YEARS FOR THE ESTIMATION OF EFFECTIVENESS OF SCREENING PROGRAMMES- A SYSTEMATIC REVIEW

    Nov 1, 2010, 00:00

  • PCV75 CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION

    Nov 1, 2010, 00:00

  • PIH16 SURGICAL REPAIR OF ANTERIOR VAGINAL WALL PROLAPSE USING PROLIFT AND COLPORRHAPHY. A COST-EFFECTIVENESS ANALYSIS FOR A THIRD LEVEL HOSPITAL IN MEXICO

    Nov 1, 2010, 00:00

  • PCV31 BASELINE HEALTH-RELATED QUALITY OF LIFE STUDY IN HONG KONG CARDIAC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2010, 00:00

  • PHP68 THE USE OF HEALTH ECONOMICS TERMINOLOGY IN CLINICAL PUBLICATIONS- BRIDGING THE GAP FROM CLINICAL EFFECTIVENESS TO COMPARATIVE EFFECTIVENESS

    Nov 1, 2010, 00:00

  • PCN12 COST-EFFECTIVENESS OF THE ONCOTYPE DX ASSAY IN AUSTRALIA- AN EXPLORATORY ANALYSIS

    Nov 1, 2010, 00:00

  • PCV122 THE IMPACT OF A CLINICAL PHARMACIST INTERVENTION ON LIPID-LOWERING IN A PRIMARY CARE SETTING

    Nov 1, 2010, 00:00

  • PCN107 FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB AND SOCIETAL COST SAVINGS IN SPAIN

    Nov 1, 2010, 00:00

  • PSY14 REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN- TREATMENT PATTERN AND COSTS

    Nov 1, 2010, 00:00

  • PMH38 A COST UTILITY ANALYSIS OF FIRST LINE ANTIPSYCHOTICS FOR THE PREVENTION OF SCHIZOPHRENIA RELAPSE IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PSS7 ECONOMIC EVALUATION ON VISION SCREENING FOR PRESCHOOL CHILDREN

    Nov 1, 2010, 00:00

  • PMC47 FURTHER INSIGHT INTO DESIGNING WEB-BASED PATIENT REPORTED OUTCOMES FOR USE ON PERSONAL COMPUTERS IN GLOBAL STUDIES

    Nov 1, 2010, 00:00

  • PCN29 EPIDEMIOLOGY AND HEALTH-CARE UTILIZATION FOR RESECTED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCHN) IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PCV16 THE EFFECT OF SITAXENTAN ON EXERCISE CAPACITY, HEMODYNAMIC FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PSY6 THE ICATIBANT OUTCOME SURVEY-A PROSPECTIVE STUDY OF SAFETY AND EFFECTIVENESS OF ICATIBANT IN A SETTING IN PATIENTS WITH HEREDITARY ANGIOEDEMA

    Nov 1, 2010, 00:00

  • PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PIH9 COST EFFECTIVENESS OF CONTRACEPTIVES IN A PACIFIC REGION COUNTRY- COLOMBIA

    Nov 1, 2010, 00:00

  • PGI25 CHILD AND PARENT REPORTS OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)- RESULTS OF QUALITATIVE INTERVIEWS

    Nov 1, 2010, 00:00

  • PHP80 EFFECTS OF REFERENCE PRICING AND TENDER CONTRACTS IN GERMANY

    Nov 1, 2010, 00:00

  • PRS3 COMORBIDITY PROFILING OF COPD PATIENTS IN THE UNITED KINGDOM PRIMARY CARE USING AN INCIDENCE BASED APPROACH TO DETECT ASSOCIATIONS WITH THE DISEASE

    Nov 1, 2010, 00:00

  • PHP15 RISK-SHARING SCHEMES WORLDWIDE- A LANDSCAPE ANALYSIS OF HEALTH OUTCOMES-BASED REIMBURSEMENT AGREEMENTS

    Nov 1, 2010, 00:00

  • NI3 NICES COST-EFFECTIVENESS THRESHOLD REVISITED- NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS

    Nov 1, 2010, 00:00

  • PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PSY57 WILLINGNESS TO PAY FOR OBESITY PHARMACOLOGY

    Nov 1, 2010, 00:00

  • PCN54 HOSPITAL UNDERTAKING OF PATIENTS WITH A RESECTION OF LUNG TUMOR IN FRANCE

    Nov 1, 2010, 00:00

  • PDB47 THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING IN TYPE 1 DIABETES PATIENTS IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PCV40 WHICH STRATEGY CAN CONTROL THE EXPENDITURE OF HIGH-PRICE DRUGS?

    Nov 1, 2010, 00:00

  • CV3 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA

    Nov 1, 2010, 00:00

  • EQ3 ESTIMATING THE SF-6D VALUE SET FOR A POPULATION BASED SAMPLE OF BRAZILIANS

    Nov 1, 2010, 00:00

  • PMS59 THE EFFECT OF TNF THERAPY, SOCIODEMOGRAPHIC AND CLINICAL FACTORS ON SLEEP DISTURBANCES AND FATIGUE AMONG RHEUMATOID ARTHRITIS-RESULTS FROM THE NDB-PORTUGAL COHORT

    Nov 1, 2010, 00:00

  • PMS34 COST-EFFECTIVENESS OF GOLIMUMAB IN PSORIATIC ARTHRITIS FROM THE UK PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • Evaluating Willingness-to-Pay Thresholds for Dementia Caregiving Interventions- Application to the Tailored Activity Program

    Sep 1, 2010, 00:00

  • Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis

    Sep 1, 2010, 00:00

  • Willingness to Pay for Lung Cancer Treatment

    Sep 1, 2010, 00:00

  • Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

    Sep 1, 2010, 00:00

  • The Unit Costs of Inpatient Hospital Days, Outpatient Visits, and Daycare Treatments in the Fields of Oncology and Hematology

    Sep 1, 2010, 00:00

  • Differences in Child versus Parent Reports of the Child's Health-Related Quality of Life in Children with Epilepsy and Healthy Siblings

    Sep 1, 2010, 00:00

  • A Competing Risks Prescription Refill Model of Compliance and Persistence

    Sep 1, 2010, 00:00

  • The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications- A Propensity Score-Weighted Difference in Difference Evaluation

    Sep 1, 2010, 00:00

  • A Multimarker Approach for the Prediction of Coronary Artery Disease- Cost-Effectiveness Analysis

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

    Sep 1, 2010, 00:00

  • Medical Services Utilization and Expenditure of Obesity-Related Disorders in Taiwanese Adults

    Sep 1, 2010, 00:00

  • Clustering Rasch Results- A Novel Method for Developing Rheumatoid Arthritis States for Use in Valuation Studies

    Sep 1, 2010, 00:00

  • An Ounce of Prevention Is Worth a Pound of Cure- A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research

    Sep 1, 2010, 00:00

  • Measuring Patient Anxiety in Primary Care- Rasch Analysis of the 6-item Spielberger State Anxiety Scale

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of Therapeutic Hypothermia to Treat Neonatal Encephalopathy

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation- Arguments for a National Approach

    Sep 1, 2010, 00:00

  • Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study

    Sep 1, 2010, 00:00

  • Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom- Findings from the INFORCE Study

    Sep 1, 2010, 00:00

  • How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

    Sep 1, 2010, 00:00

  • The Cost-Effectiveness of Spinal Cord Stimulation for Complex Regional Pain Syndrome

    Sep 1, 2010, 00:00

  • The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications

    Sep 1, 2010, 00:00

  • Modeling the Long-Term Cost-Effectiveness of the Caries Management System in an Australian Population

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation across Jurisdictions

    Sep 1, 2010, 00:00

  • A Valuation of Infusion Therapy to Preserve Islet Function in Type 1 Diabetes

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Duloxetine- The Stress Urinary Incontinence Treatment (SUIT) Study

    Jul 1, 2010, 00:00

  • A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

    Jul 1, 2010, 00:00

  • General Population Reference Values for the French Version of the EuroQol EQ-5D Health Utility Instrument

    Jul 1, 2010, 00:00

  • Cost–Utility Analysis of Topical Intranasal Steroids for Otitis Media with Effusion Based on Evidence from the GNOME Trial

    Jul 1, 2010, 00:00

  • Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patients

    Jul 1, 2010, 00:00

  • Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients

    Jul 1, 2010, 00:00

  • The Cost-Effectiveness of Group Cognitive Behavioral Therapy Compared with Routine Primary Care for Women with Postnatal Depression in the UK

    Jul 1, 2010, 00:00

  • A Portuguese Value Set for the SF-6D

    Jul 1, 2010, 00:00

  • Evaluating Interventions to Improve Antiretroviral Adherence- How Much of an Effect Is Required for Favorable Value?

    Jul 1, 2010, 00:00

  • Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer

    Jul 1, 2010, 00:00

  • Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis

    Jul 1, 2010, 00:00

  • Network Meta-Analysis- Importance of Appropriate Trial Selection

    Jul 1, 2010, 00:00

  • Abolition of Prescription Copayments in Wales- An Observational Study on Dispensing Rates

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China- A Markov Analysis

    Jul 1, 2010, 00:00

  • Assessing the Economic Value of Public Health Programs Based on Risk- The Case of the Cancer Plan in France

    Jul 1, 2010, 00:00

  • The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines

    Jul 1, 2010, 00:00

  • A Cost-Utility Analysis of Microwave Endometrial Ablation versus Thermal Balloon Endometrial Ablation

    Jul 1, 2010, 00:00

  • Response to Comments on “No Study Left Behind- A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”

    Jul 1, 2010, 00:00

  • Early-Stage Valuation of Medical Devices- The Role of Developmental Uncertainty

    Jul 1, 2010, 00:00

  • Eliciting Distributions to Populate Decision Analytic Models

    Jul 1, 2010, 00:00

  • Empirically Evaluating Decision-Analytic Models

    Jul 1, 2010, 00:00

  • Consequences of Screening in Lung Cancer- Development and Dimensionality of a Questionnaire

    Jul 1, 2010, 00:00

  • Populating an Economic Model with Health State Utility Values- Moving toward Better Practice

    Jul 1, 2010, 00:00

  • Incorporating Equity–Efficiency Interactions in Cost-Effectiveness Analysis—Three Approaches Applied to Breast Cancer Control

    Jul 1, 2010, 00:00

  • Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation

    Jun 1, 2010, 00:00

  • Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries

    Jun 1, 2010, 00:00

  • Social Time Preferences for Health and Money Elicited with a Choice Experiment

    Jun 1, 2010, 00:00

  • Editorial

    Jun 1, 2010, 00:00

  • An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

    Jun 1, 2010, 00:00

  • Response to- A Methodology for Successfully Producing Global Translations of Patient-Reported Outcomes Measures for Use in Multiple Countries by Two et al.

    Jun 1, 2010, 00:00
  • «
  • 131
  • 132
  • 133 (current)
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • »